TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models Meeting Abstract
| Authors: | O'Donohue, T.; Ibáñez, G.; Mauguen, A.; Siddiquee, A.; Rosales, N.; Calder, P.; Ndengu, A.; Roberts, S.; Dela Cruz, F.; Kung, A. |
| Abstract Title: | TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models |
| Meeting Title: | 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 138 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2020 Oct 24-25 |
| Meeting Location: | Virtual |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-10-01 |
| Start Page: | S16 |
| End Page: | S17 |
| Language: | English |
| ACCESSION: | WOS:000582839900036 |
| PROVIDER: | wos |
| DOI: | 10.1016/s0959-8049(20)31108-4 |
| Notes: | Meeting abstract: 34 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work